[
  {
    "ts": null,
    "headline": "Why Moderna (MRNA) Stock Is Falling Today",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an announcement about a new, early-stage study.",
    "url": "https://finnhub.io/api/news?id=e058fc2748e808ad707833f7fc5149e43f12a0a1cf0c7a72f91672fe1211a16f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762194043,
      "headline": "Why Moderna (MRNA) Stock Is Falling Today",
      "id": 137306194,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its financial performance and a recent clinical setback overshadowed an announcement about a new, early-stage study.",
      "url": "https://finnhub.io/api/news?id=e058fc2748e808ad707833f7fc5149e43f12a0a1cf0c7a72f91672fe1211a16f"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma",
    "summary": "CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants ...",
    "url": "https://finnhub.io/api/news?id=bf4b0aaa4ac81b4593a69fd1ed8b538de1e6333e3fef9434b16683c7ecfd7c73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762171200,
      "headline": "Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma",
      "id": 137303569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company's investigational mRNA-based T-cell engager (TCE) for participants ...",
      "url": "https://finnhub.io/api/news?id=bf4b0aaa4ac81b4593a69fd1ed8b538de1e6333e3fef9434b16683c7ecfd7c73"
    }
  },
  {
    "ts": null,
    "headline": "Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark",
    "summary": "George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.",
    "url": "https://finnhub.io/api/news?id=bc4a73786f98e345047b1a3d315599d55745b877699bdd9c908fde8c3cef74ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762164000,
      "headline": "Tidmarsh resigns from CDER; Kenvue to sell to Kimberly-Clark",
      "id": 137304088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "George Tidmarsh’s short run directing the agency’s principal drug review office reportedly ended in controversy. Elsewhere, Moderna advanced a T-cell engager and Lilly expanded a production push for its GLP-1 pill.",
      "url": "https://finnhub.io/api/news?id=bc4a73786f98e345047b1a3d315599d55745b877699bdd9c908fde8c3cef74ac"
    }
  }
]